Compounds with 5-ht1a activity useful for treating disorders of the outer retina

Abstract

Compositions and methods for treating disorders of the outer retina with compounds with 5-HT 1A against activity are disclosed.

We claim:  
     
         1 . A method for treating disorders of the outer retina which comprises administering a pharmaceutically effective amount of a compound with 5-HT 1A  agonist activity.  
     
     
         2 . The method of  claim 1 , wherein the compound is selected from the group consisting of: tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, E-5842, SUN-N4057, Org-13011, Org-12966 and 8-OH-DPAT.  
     
     
         3 . The method of  claim 1  wherein the disorder is selected from the group consisting of: AMD; RP and other forms of heredodegenerative retinal disease; retinal detachment and tears; macular pucker; ischemia affecting the outer retina; diabetic retinopathy; damage associated with laser therapy (grid, focal, and panretinal) including photodynamic therapy (PDT); trauma; surgical (retinal translocation, subretinal surgery, or vitrectomy) or light-induced iatrogenic retinopathy; and preservation of retinal transplants.  
     
     
         4 . The method of  claim 3  wherein the disorder is AMD.  
     
     
         5 . The method of  claim 3  wherein the compound is selected from the group consisting of: tandospirone, urapidil, ziprasidone, repinotan hydrochloride, xaliproden hydrochloride (SR-57746A), buspirone, flesinoxan, EMD-68843, DU-127090, gepirone, alnespirone, PNU-95666, AP-521, flibanserin, MKC-242, lesopitron, sarizotan hydrochloride, E-5842, SUN-N4057, Org-13011, Org-12966 and 8-OH-DPAT.  
     
     
         6 . The method of  claim 5  wherein the disorder is selected from the group consisting of AMD, RP, and diabetic retinopathy.